ADVERTISEMENT

Stay up to date every week with the european biotechnology newsletter.

✕
This field is for validation purposes and should be left unchanged.
This field is hidden when viewing the form
EBcom NL
This field is hidden when viewing the form
Consent

Stay up to date every week with the european biotechnology newsletter.

Log in here to read the desired article.

This field is for validation purposes and should be left unchanged.
This field is hidden when viewing the form
EBcom NL
This field is hidden when viewing the form
Consent
go to the article

go back to the homepage

  • Subscription
  • Newsletter
  • Advertise
European Biotechnology Magazine
biocom_logo
  • Latest news
  • Background
  • Opinion
  • The Mag
    • Issues
    • Special
    • Corporate publications
    • Subscribe
  • Euro Biotech Guide
  • Market Place
    • Products
    • Sponsored Publications
    • Advertise
  • Associations
  • Service
    • Newsletter
    • Contact Us
    • Editorial Team
  • Events
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu

ADVERTISEMENT

The Boltz team.
artificial intelligence

Boltz raises $110M after 50-fold surge in AI usage

London-based Boltz has raised $110 million (€100 million) in a Series A led by Bessemer Venture Partners to expand its AI platform for designing small-molecule drugs and therapeutic proteins. The financing … more ➔

20 pound bill
investment

British Business Bank commits over £1B to life sciences

The British Business Bank has surpassed £1 billion in cumulative support for the U.K. life sciences sector, reaching £1.13 billion (€1.36 billion) through commitments to specialist investment funds … more ➔

ADVERTISEMENT

neuron brain connection
clinical data

Priavoid’s Alzheimer’s drug misses Phase 2 efficacy endpoint

German biotech Priavoid has missed the primary efficacy endpoint in a Phase 2 trial of its oral Alzheimer’s drug PRI-002. However, the company reported encouraging signs of cognitive benefit in longer-term … more ➔

Image credit: Warren Umoh via Unsplash+
precision medicine

Oxford-based Genomics keeps Vertex on board for another four years, potential $220M deal

U.S. biotech Vertex Pharmaceuticals has extended its drug discovery partnership with Oxford-based Genomics Limited by an additional four years in a deal the U.K. company says could exceed $220 million … more ➔

disco ball party
licensing

After Amgen, DISCO lands AbbVie deal worth up to $2.5B

Cologne-based DISCO Pharmaceuticals has signed a cancer drug discovery deal with AbbVie, securing $40 million (€36.5 million) upfront and potentially up to $2.5 billion (€2.3 billion) in additional … more ➔

European Biotechnology

1 / 4
EBM 3.2026 Autumn_cover

The autumn issue of European Biotechnology magazine asks what happens when biotech leaves Earth. Our cover story explores how microgravity could help researchers study disease, improve drug formulations … more ➔

Get a free sample copy | Abo
2 / 4

The summer issue of European Biotechnology Magazine showcases the latest developments in drug delivery and RNA technologies. This issue features a list of eight venture capital firms to watch in 2026. … more ➔

Get a free sample copy | Abo
3 / 4

The Spring 2026 issue of European Biotechnology Magazine presents a list of start-ups to watch in 2026 and explores other fascinating topics such as: Can biotechnology finally fix infertility? Can … more ➔

Get a free sample copy | Abo
4 / 4
EB425_Cover

Europe is losing much of its expertise in deep tech and life sciences to the US. To prevent another generation of innovation from being lost, Europe must close the funding gaps. more ➔

Get a free sample copy | Abo

ADVERTISEMENT

© AI
european-biotechnology-logo

NEWSLETTER


Stay up to date with the biotech industry!

Once a week, european-biotechnology.com brings you up to date on the latest developments in the biotech industry. In our free newsletter, you will find the latest news from business, research and politics, as well as lots of useful information and job vacancies.


Subscribe to our free newsletter!Subscribe here

Demis Hassabis
artificial intelligence

Isomorphic Labs raises $5B six months after $2.1B round

London-based Isomorphic Labs has raised $5 billion (€4.5 billion) in a Series C co-led by Greenoaks and Sequoia Capital, just six months after securing $2.1 billion. The latest financing takes the … more ➔

Image credit: Allison Saeng via Unsplash+
Alzheimer’s Disease

AmyriAD picks up Alzheimer’s drug that began as a trial control

Dutch biotech AmyriAD Therapeutics has added a second clinical-stage drug in six weeks, buying worldwide rights to the Alzheimer’s candidate AD04 from Miami-based ADvantage Therapeutics on undisclosed … more ➔

ADVERTISEMENT

Sponsored Publications

Picture credit: Lumis International
clinical trial

Geopolitical shifts in trial outsourcing

Three developments over the past year have changed what “outsourcing” a clinical trial actually means. New U.S. tariffs on patented pharmaceuticals, a revised Chinese trial standard, and faster … more ➔

APPOINTMENTS

all appointments

eb.com_Jeff_Abbey_Spica_Therapeutics_CEOSpica Therapeutics
Spica Therapeutics

New CEO for the next level

The Belgian biotech company Spica Therapeutics, specialist for Macrophages biology, appointed Jeff Abbey as new Chief Executive Officer …
more ➔

EB.com_Qiagen_CEO_Jonathan_PrattQiagen
Qiagen

New CEO took over the reins

At the beginning of September, Jonathan M. Pratt succeeded Thierry Bernard as CEO of Qiagen N.V. Bernard had led the biotech pioneer …
more ➔

Samanta CimitanLonza Group
CDMO

Samanta Cimitan to (re)join Lonza from Celonic

Samanta Cimitan will join Lonza as Chief Commercial Officer (CCO), Senior Vice President and a member of the Extended Executive Committee …
more ➔

eb.com_Teresa Nunes CMO_EpilepsyGTXEpilepsyGTX
EpilepsyGTX

Clinical Development Expert has started

London-based EpilepsyGTx has appointed Dr Teresa Nunes as Chief Medical Officer (CMO) to support the continued development of the company’s …
more ➔

Meanwhile in Biotech - European Biotechnology news roundup
Meanwhile in biotech

Cellectis plans 70% workforce cuts; Sanofi signs $1.2B DNA medicines deal; AstraZeneca buys Omniose

This week in our news roundup: Cellectis’ shift toward in vivo gene editing comes with steep workforce cuts, while Sanofi and AstraZeneca add new technologies through deals. Elsewhere, respiratory … more ➔

ADVERTISEMENT

commit or quit
fundraising

Commit Biologics secures $60M to advance complement-based immunotherapies

Danish biotech Commit Biologics has completed a $60 million (€54 million) seed financing round to advance its first complement-powered immune engager toward clinical trials. The closing follows the … more ➔

brain scan neon
research collaboration

TRIMTECH lands $411M Biogen deal for neurodegeneration protein degraders

Cambridge-based TRIMTECH Therapeutics has signed a research collaboration and licensing option agreement with Biogen to develop small-molecule protein degraders for neurodegenerative diseases. The deal … more ➔

All news
newsletter_link

EVENT


PharmaLab2025_event_lsiting_ohne-EB
November 23 - November 25in Darmstadt

PharmaLab Congress and Exhibition 2026 at a new venue

The event for all pharmaceutical laboratory sectors will continue its success story for the 14th time on 23-25 November 2026 - now at a new venue in Darmstadt (near Frankfurt Airport): the darmstadtium, a modern conference centre with state-of-the-art and sustainable technical facilities. ➔

Knowbio GmbH
  • Link to LinkedIn
  • Link to Instagram
  • Contact
  • Imprint
  • Privacy policy
Scroll to top Scroll to top Scroll to top